Acyclovir halts progression of herpes zoster in immunocompromised patients.

We conducted a placebo-controlled, double-blind study of acyclovir therapy for acute herpes zoster in immunocompromised patients. Of the 94 patients enrolled in the study, 52 had localized skin lesions at entry, and 42 had disseminated cutaneous zoster. A one-week course of intravenous acyclovir (1500 mg per square meter of body-surface area per day) halted progression of zoster in both groups, as determined by development or progression of cutaneous dissemination, development of visceral zoster, or proportion of cases deemed treatment failures. Significantly fewer patients treated with acyclovir within the first three days after the onset of exanthem had complications of zoster, as compared with patients treated with placebo (P = 0.02 by Fisher's exact test), but acyclovir also stopped progression of zoster in patients treated after three days of rash (P = 0.05 by Fisher's exact test). Acyclovir recipients with disseminated cutaneous zoster had a significantly accelerated rate of clearance of virus from vesicles, as compared with placebo recipients (P = 0.05 by the Breslow test).
AuthorsH H Balfour Jr, B Bean, O L Laskin, R F Ambinder, J D Meyers, J C Wade, J A Zaia, D Aeppli, L E Kirk, A C Segreti, R E Keeney
JournalThe New England journal of medicine (N Engl J Med) Vol. 308 Issue 24 Pg. 1448-53 (Jun 16 1983) ISSN: 0028-4793 [Print] UNITED STATES
PMID6343861 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Acyclovir
  • Acyclovir (adverse effects, therapeutic use)
  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Herpes Zoster (complications, drug therapy)
  • Humans
  • Immunologic Deficiency Syndromes (complications)
  • Leukemia (complications)
  • Lymphoma (complications)
  • Male
  • Middle Aged
  • Neoplasms (complications)
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: